The vaccine window will focus on new, under-used, and newly licensed vaccines to combat the diseases causing a significant proportion of child mortality. In the near term, IFFIm funds would be used to stimulate increased manufacturing capacity for the combination DTP-HepB and DTP-HepB-Hib vaccines - vaccines which are currently supported by GAVI and the GAVI Fund but which are not produced in enough capacity, or at the prices that would satisfy current demand. New vaccines against rotavirus and meningococcus A could have significant impact on reducing disease burden.

GAVI’s experience demonstrates that co-financing arrangements with countries greatly improves the prospects for long-term sustainability and would allow for the extension of IFFIm funding to more countries over a longer period of time. When vaccines are first introduced in developing countries, the high prices put them out of reach of developing country health budgets. GAVI, through IFFIm funding, is able to shoulder much of this funding burden. However, over time, vaccine prices are expected to decrease, eventually reaching a point where developing countries can take over the financing of these vaccines.